undamentalytics Newsletter
Sign in

Ensysce Biosciences, Inc. revenue

Ensysce Biosciences, Inc.'s revenue was $5.1m in fiscal 2025, down 2.8% on the year before. Since fiscal 2020 ($3.9m) it has grown at a compound 5.2% a year. Over the last twelve months it was $4.5m.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue3,9313,5312,5232,2315,2105,0674,501
Growth on the year before—−10.2%−28.5%−11.6%+133.6%−2.8%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Ensysce Biosciences, Inc. $4.5m -39.3% 14.6%
Ocugen, Inc. $4.6m -3.7% 26.3%
Entrada Therapeutics, Inc. $4.7m -94.1% —
Curis Inc $4.3m -62.2% -25.0%
Bolt Biotherapeutics, Inc. $4.7m 12.8% -11.5%
Camp4 Therapeutics Corp $4.2m 40.2% —

Compare with peers

Head to head: ENSC vs OCGNENSC vs TRDACRIS vs ENSCCAMP vs ENSC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ensysce Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ensysce Biosciences, Inc.